NRX Pharmaceuticals (NRXP) Accounts Payables (2017 - 2026)

NRX Pharmaceuticals (NRXP) has 10 years of Accounts Payables data on file, last reported at $4.4 million in Q1 2026.

• On a quarterly basis, Accounts Payables rose 2.04% year-over-year to $4.4 million in Q1 2026; TTM through Mar 2026 was $4.4 million, a 2.04% increase from a year earlier, with the FY2025 full-year figure at $4.3 million, up 3.39% from the prior year.
• Accounts Payables for Q1 2026 stood at $4.4 million, up from $4.3 million in the prior quarter.
• Over the last five years, Accounts Payables for NRXP reached as high as $6.3 million in Q1 2024 and fell as low as $2.1 million in Q4 2022.
• Historically, Accounts Payables has averaged $3.9 million across 5 years, with a median of $4.3 million in 2025.
• On a YoY basis, Accounts Payables climbed as much as 569.73% in 2022 and fell as far as 61.0% in 2022.
• Year by year, Accounts Payables stood at $2.1 million in 2022, then soared by 123.12% to $4.6 million in 2023, then fell by 10.84% to $4.1 million in 2024, then advanced by 3.39% to $4.3 million in 2025, then gained by 3.02% to $4.4 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $4.4 million in Q1 2026, $4.3 million in Q4 2025, and $4.3 million in Q3 2025.